In Vivo Animal Studies
The Toxicology and Cancer Biology Program has extensive experience in designing, conducting, evaluating, and interpreting study results that cover various endpoint analyses (clinical pathology, biochemical and molecular) for submission to regulatory agencies as well as for research and development.
Services
General Toxicology Services
- Administration of Test Article (e.g. oral, subcutaneous, intravenous, intradermal, intratracheal, high pressure tail vein injections, footpad, aspiration, feed, water, osmotic minipumps, pellets, and implantation)
- Rodent Models of Disease
- Study Design, Protocol Development and Implementation
- Animal Model selection and development
- Dose Formulation and Analyis
- Data Collection, Statistical Analysis and Scientific Interpretation
- Final Report Generation
- Animal Studies for Mechanistic-Based Research
- Cell proliferation, cell cycle and apoptosis
- Pharmacokinetic and ADME Studies
- Xenograft and orthotopic transplantation
- Strain-specific phenotypic differential effects
Necropsy and Tissue/Sample Collection
- Characterization/Grading/Mapping of Lesions
- Urine, Fecal and Blood Collection
- Tissue Collection for DNA, RNA, and protein Isolation
- Whole body/live longitudinal animal imaging
- Cell sorting/isolation and characterization
- Whole body and organ perfusion
- Caliper Measurements and specialized surgical techniques
Toxicology Studies and Cancer Bioassays
- Cancer Bioassay
- Neurotoxicity/behavior testing (FOB )
- Vaccine Safety and Efficacy
- Reproductive and developmental toxicity
- Immunotoxicity
- Acute and chronic toxicity testing
- Toxico-pharmacokinetic Studies
- Chemoprevention studies
- Endocrine Tier 1 testing assays (in vivo mammalian assays only)
Animal Models
- Conventional models of rats and mice
- Immuno-compromised animal tudies
- Breeding, genotyping, phenotyping and various animal modes of disease
- Breeding animals for protocol specific research studies
- Transgenic: genotypic, phenotypic, and histopathological characterization
- Breeding onto susceptible background strain
- Fostering pups
Special Studies
- Medical device: specialized surgical techniques for implantation and extraction
- Nanoparticle: distribution and toxicity
Lead Scientist
Glenda Moser, Ph.D. DABT
Phone: 919 281-1110 Ext. 723
Email: (JavaScript must be enabled to view this email address)
Dr. Moser has over 20 years of experience in in vivo and in vitro studies. She has managed and successfully supervised studies evaluating gene and protein expression as early endpoint predictors of phenotypic alterations. Dr. Moser is responsible for the development of Standard Operating Procedures (SOPs) and the quality control and training programs in the toxicology division. She is responsible for compliance to pertinent policies, rules and regulations for the AAALAC, PHS policy, Animal Welfare Act, and United States Department of Agriculture (USDA). She has conducted in vivo studies under Good Laboratory Practices, Guidelines for submission to the EPA, FDA, and Organisation for Economic Co-operation and Development (OECD). She also responds to the ILS and NIEHS IACUCs. Dr. Moser has extensive experience in designing, implementing, and managing research studies, conducting statistical analysis, and writing protocols, and manuscripts. Dr. Moser received both her M.S. and Ph.D. in Toxicology and Pharmacology from North Carolina State University where she published seven manuscripts describing the mechanisms of mirex-induced skin tumors with mutations in the Ha-ras gene and the toxicant-induced disruption of signal transduction pathways.